No difference on survival for patients with metastatic castration-resistant prostate cancer treated with apalutamide-abiraterone combination therapy

Prolonged radiologically progression-free survival did not transfer into better overall survival in men with metastatic castration-resistant prostate cancer (mCRPC) treated with two androgen-targeted drugs instead of one.